BMC Neurology (Oct 2011)

Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study

  • Bastianello Stefano,
  • Romani Alfredo,
  • Viselner Gisela,
  • Tibaldi Enrico,
  • Giugni Elisabetta,
  • Altieri Marta,
  • Cecconi Pietro,
  • Mendozzi Laura,
  • Farina Massimiliano,
  • Mariani Donatella,
  • Galassi Antonio,
  • Quattrini Claudio,
  • Mancini Marcello,
  • Bresciamorra Vincenzo,
  • Lagace Angela,
  • McDonald Sandy,
  • Bono Giorgio,
  • Bergamaschi Roberto

DOI
https://doi.org/10.1186/1471-2377-11-132
Journal volume & issue
Vol. 11, no. 1
p. 132

Abstract

Read online

Abstract Background Chronic cerebrospinal venous insufficiency (CCSVI) has recently been reported to be associated with multiple sclerosis (MS). However, its actual prevalence, possible association with specific MS phenotypes, and potential pathophysiological role are debated. Method We analysed the clinical data of 710 MS patients attending six centres (five Italian and one Canadian). All were submitted to venous Doppler sonography and diagnosed as having or not having CCSVI according to the criteria of Zamboni et al. Results Overall, CCSVI was diagnosed in 86% of the patients, but the frequency varied greatly between the centres. Even greater differences were found when considering singly the five diagnostic criteria proposed by Zamboni et al. Despite these differences, significant associations with clinical data were found, the most striking being age at disease onset (about five years greater in CCSVI-positive patients) and clinical severity (mean EDSS score about one point higher in CCSVI-positive patients). Patients with progressive MS were more likely to have CCSVI than those with relapsing-remitting MS. Conclusion The methods for diagnosing CCSVI need to be refined, as the between-centre differences, particularly in single criteria, were excessively high. Despite these discrepancies, the strong associations between CCSVI and MS phenotype suggest that the presence of CCSVI may favour a later development of MS in patients with a lower susceptibility to autoimmune diseases and may increase its severity.